866157-50-8

Basic information

• Product Name: Ozagrel methylester
• Synonyms: Ozagrel methylester;3-[4-(1H-Imidazol-1-yl)phenyl]-2-propenoic acid methyl ester;-Propenoicacid, 3-[4-(1H-iMidazol-1-yl)phenyl]-, Methyl ester;Methyl (2E)-3-[4-(1H-iMidazol-1-ylMethyl)phenyl]prop-2-enoate;Ozagrel methyl ester 3-[4-(1H-Imidazol-1-yl)phenyl]-2-propenoic acid methyl ester;(E)-methyl 3-(4-((1H-imidazol-1-yl)methyl)phenyl)acrylate;Methyl 3-(4-(1H-imidazol-1-yl)phenyl)acrylate
• CAS NO: 866157-50-8
• Molecular Formula: C₁₃H₁₂N₂O₂
• Molecular Weight: 242.27316
• Mol File: 866157-50-8.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 431.8°C at 760 mmHg
• Flash Point: 214.9°C
• Appearance: /
• Density: 1.12
• Vapor Pressure: 1.17E-07mmHg at 25°C
• Refractive Index: 1.56
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 5.42±0.10(Predicted)
• CAS DataBase Reference: Ozagrel methylester(CAS DataBase Reference)
• NIST Chemistry Reference: Ozagrel methylester(866157-50-8)
• EPA Substance Registry System: Ozagrel methylester(866157-50-8)

Safety Data

• Hazardous Substances Data: 866157-50-8(Hazardous Substances Data)

Usage

InChI:InChI=1/C14H14N2O2/c1-18-14(17)7-6-12-2-4-13(5-3-12)10-16-9-8-15-11-16/h2-9,11H,10H2,1H3/b7-6+

Upstream product

• 5927-18-4 trimethyl phosphonoacetate 
• 10040-98-9 1-(4-formylphenyl)-1H-imidazole 

Relevant articles and documents

Cinnamide compound

The present invention relates to a compound represented by Formula (I): (wherein Ar1 represents an imidazolyl group which may be substituted with 1 to 3 substituents; Ar2 represents a pyridinyl group, a pyrimidinyl group, or a phenyl group which may be substituted with 1 to 3 substituents; X1 represents (1) —C≡C— or (2) a double bond etc. which may be substituted; R1 and R2 represent, for example, a C1-6 alkyl group or C3-8 cycloalkyl group which may be substituted) or a pharmacologically acceptable salt thereof and to the use thereof as pharmaceutical agents. The object of the present invention is to find a therapeutic or preventive agent for diseases caused by Aβ. According to the present invention, a therapeutic or preventive agents for diseases caused by Aβ can be provided.